Influence of APOE-2 genotype on the relation between adiposity and plasma lipid levels in patients with vascular disease

被引:17
作者
Koopal, C. [1 ]
van der Graaf, Y. [2 ]
Asselbergs, F. W. [3 ,4 ,5 ]
Westerink, J. [1 ]
Visseren, F. L. J. [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Vasc Med, NL-3508 GA Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Dept Cardiol, Div Heart & Lungs, NL-3508 GA Utrecht, Netherlands
[4] ICIN Netherlands Heart Inst, Durrer Ctr Cardiogenet Res, Utrecht, Netherlands
[5] UCL, Inst Cardiovasc Sci, Fac Populat Hlth Sci, London, England
关键词
III HYPERLIPOPROTEINEMIA; APOLIPOPROTEIN-E; METABOLIC SYNDROME; POLYMORPHISM; MANAGEMENT; DYSBETALIPOPROTEINEMIA; PATHOGENESIS; CHOLESTEROL; EXPRESSION; DIAGNOSIS;
D O I
10.1038/ijo.2014.105
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Apolipoprotein E (APOE) genotypes are associated with different plasma lipid levels. People with the APO epsilon 2 genotype can develop a disorder called dysbetalipoproteinemia (DBL). A possible predisposing factor for DBL is adiposity. We evaluated whether and to what extent the APOE genotype modifies the relation between adiposity and lipids in patients with manifest arterial disease and we looked at possible determinants of DBL in epsilon 2 homo-and heterozygote patients. METHODS: This prospective cohort study was performed in 5450 patients with manifest arterial disease from the Secondary Manifestations of ARTerial disease (SMART) study. The APOE genotype was measured in all patients and revealed 58 epsilon 2 homozygotes, 663 epsilon 2 heterozygotes, 3181 epsilon 3 homozygotes and 1548 epsilon 4 carriers. The main dependent variable was non-highdensity lipoprotein cholesterol (non-HDL-c). The relation between adiposity (including body mass index (BMI), waist circumference (waist), visceral adipose tissue (VAT) and metabolic syndrome (MetS)) and lipids was evaluated with linear regression analyses. Determinants of DBL were evaluated using logistic regression. RESULTS: There was significant effect modification by the APOE genotype on the relation between non-HDL-c and BMI, waist, VAT and MetS. There was an association between BMI and non-HDL-c in e2 homozygotes (beta 0.173, 95% confidence interval (CI) 0.031-0.314, P = 0.018) and e4 carriers (beta 0.033, 95% CI 0.020-0.046, P < 0.001). In all genotypes, there was an effect of waist, VAT and MetS on non-HDL-c, but these effects were most distinct in e2 homozygotes (waist beta 0.063, 95% CI 0.015-0.110, P = 0.011; VAT beta 0.580, 95% CI 0.270-0.889, P = 0.001; MetS beta 1.760, 95% CI 0.668-2.852, P = 0.002). Determinants of DBL in epsilon 2 homo-and heterozygotes were VAT and MetS. CONCLUSION: The APOE genotype modifies the relation between adiposity and plasma lipid levels in patients with vascular disease. The relation between adiposity and lipids is present in all patients, but it is most distinct in epsilon 2 homozygote patients. Abdominal fat and MetS are determinants of DBL.
引用
收藏
页码:265 / 269
页数:5
相关论文
共 26 条
[1]  
[Anonymous], 2003, APPL MULTIPLE REGRES, DOI DOI 10.1111/J.1365-2575.2007.00238.X
[2]   Association of apolipoprotein E genotypes with lipid levels and coronary risk [J].
Bennet, Anna M. ;
Di Angelantonio, Emanuele ;
Ye, Zheng ;
Wensley, Frances ;
Dahlin, Anette ;
Ahlbom, Anders ;
Keavney, Bernard ;
Collins, Rory ;
Wiman, Bjoern ;
de Faire, Ulf ;
Danesh, John .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (11) :1300-1311
[3]  
Blom DJ, 2002, SAMJ S AFR MED J, V92, P892
[4]   Interactions between lifestyle-related factors and the ApoE polymorphism on plasma lipids and apolipoproteins - The EARS study [J].
Boer, JMA ;
Ehnholm, C ;
Menzel, HJ ;
Havekes, LM ;
Rosseneu, M ;
OReilly, DS ;
Tiret, L .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (09) :1675-1681
[5]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[6]   Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158→Cys) homozygotes is associated with hyperinsulinemia [J].
de Beer, F ;
Stalenhoef, AFH ;
Hoogerbrugge, N ;
Kastelein, JJP ;
Leuven, JAG ;
van Duijn, CM ;
Havekes, LM ;
Smelt, AHM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (02) :294-299
[7]   Review: A gentle introduction to imputation of missing values [J].
Donders, A. Rogier T. ;
van der Heijden, Geert J. M. G. ;
Stijnen, Theo ;
Moons, Karel G. M. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2006, 59 (10) :1087-1091
[8]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[9]   Diagnosis and management of the metabolic syndrome - An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [J].
Grundy, SM ;
Cleeman, JI ;
Daniels, SR ;
Donato, KA ;
Eckel, RH ;
Franklin, BA ;
Gordon, DJ ;
Krauss, RM ;
Savage, PJ ;
Smith, SC ;
Spertus, JA ;
Costa, F .
CIRCULATION, 2005, 112 (17) :2735-2752
[10]   The expression of type III hyperlipoproteinemia: involvement of lipolysis genes [J].
Henneman, Peter ;
van der Sman-de Beer, Femke ;
Moghaddam, Payman Hanifi ;
Huijts, Petra ;
Stalenhoef, Anton F. H. ;
Kastelein, John J. P. ;
van Duijn, Cornelia M. ;
Havekes, Louis M. ;
Frants, Rune R. ;
van Dijk, Ko Willems ;
Smelt, Augustinus H. M. .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2009, 17 (05) :620-628